PL2310044T3 - Immunoterapia przeciwnowotworowa - Google Patents

Immunoterapia przeciwnowotworowa

Info

Publication number
PL2310044T3
PL2310044T3 PL09776746T PL09776746T PL2310044T3 PL 2310044 T3 PL2310044 T3 PL 2310044T3 PL 09776746 T PL09776746 T PL 09776746T PL 09776746 T PL09776746 T PL 09776746T PL 2310044 T3 PL2310044 T3 PL 2310044T3
Authority
PL
Poland
Prior art keywords
tumor immunotherapy
immunotherapy
tumor
Prior art date
Application number
PL09776746T
Other languages
English (en)
Inventor
Gilberto Filaci
Francesco Indiveri
Paolo Traverso
Original Assignee
Mediolanum Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediolanum Farmaceutici S.P.A. filed Critical Mediolanum Farmaceutici S.P.A.
Publication of PL2310044T3 publication Critical patent/PL2310044T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL09776746T 2008-06-16 2009-06-16 Immunoterapia przeciwnowotworowa PL2310044T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6177808P 2008-06-16 2008-06-16

Publications (1)

Publication Number Publication Date
PL2310044T3 true PL2310044T3 (pl) 2017-04-28

Family

ID=41507473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09776746T PL2310044T3 (pl) 2008-06-16 2009-06-16 Immunoterapia przeciwnowotworowa

Country Status (14)

Country Link
US (1) US8828403B2 (pl)
EP (1) EP2310044B1 (pl)
JP (1) JP5787752B2 (pl)
CA (1) CA2727388C (pl)
CY (1) CY1118215T1 (pl)
DK (1) DK2310044T3 (pl)
ES (1) ES2602453T3 (pl)
HR (1) HRP20161434T1 (pl)
HU (1) HUE030984T2 (pl)
LT (1) LT2310044T (pl)
PL (1) PL2310044T3 (pl)
PT (1) PT2310044T (pl)
SI (1) SI2310044T1 (pl)
WO (1) WO2010003520A2 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2581800C2 (ru) 2010-02-16 2016-04-20 Ультимовакс Ас Полипептиды
WO2013169060A1 (ko) 2012-05-11 2013-11-14 주식회사 카엘젬백스 패혈증 예방 또는 치료용 조성물
CN108949717B (zh) * 2012-05-11 2023-06-20 珍白斯凯尔有限公司 抗炎性肽及包含其的组合物
US10967000B2 (en) 2012-07-11 2021-04-06 Gemvax & Kael Co., Ltd. Cell-penetrating peptide, conjugate comprising same and composition comprising same
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
KR102201430B1 (ko) * 2012-09-19 2021-01-12 주식회사 젬백스앤카엘 세포 투과성 펩티드, 그를 포함한 컨쥬게이트 및 그를 포함한 조성물
TWI655204B (zh) * 2012-09-19 2019-04-01 韓商傑姆維克斯＆凱爾有限公司 穿膜胜肽以及包含該胜肽之共軛物及組成物(三)
KR102093093B1 (ko) * 2012-12-13 2020-03-25 주식회사 젬백스앤카엘 피부 노화 개선용 조성물
ES2716870T3 (es) * 2013-04-19 2019-06-17 Gemvax & Kael Co Ltd Composición para el tratamiento y prevención de lesión isquémica
CA2912557A1 (en) 2013-06-07 2014-12-11 Gemvax & Kael Co., Ltd. Biological markers useful in cancer immunotherapy
KR102166545B1 (ko) * 2013-06-21 2020-10-16 주식회사 젬백스앤카엘 호르몬 분비 조절제, 이를 포함하는 조성물, 및 이를 사용한 호르몬 분비 조절 방법
KR102204476B1 (ko) * 2013-08-14 2021-01-19 주식회사 젬백스앤카엘 다발성 경화증 치료 및 예방용 조성물
KR101691479B1 (ko) 2013-10-23 2017-01-02 주식회사 젬백스앤카엘 전립선 비대증 치료 및 예방용 조성물
WO2015072750A1 (ko) * 2013-11-12 2015-05-21 주식회사 카엘젬백스 항염증 활성을 갖는 펩티드 및 이를 포함하는 조성물
KR102494803B1 (ko) * 2013-11-22 2023-02-06 주식회사 젬백스앤카엘 혈관 신생 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
ES2809251T3 (es) 2013-12-17 2021-03-03 Gemvax & Kael Co Ltd Composición para tratar cáncer de próstata
CN106456697B (zh) 2014-04-11 2019-12-17 珍白斯凯尔有限公司 具有纤维化抑制活性的肽和含有其的组合物
ES2962532T3 (es) 2014-04-30 2024-03-19 Gemvax & Kael Co Ltd Composición para el trasplante de órganos, tejidos o células, kit y procedimiento de trasplante
KR102413243B1 (ko) 2014-12-23 2022-06-27 주식회사 젬백스앤카엘 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물
EP3263122B1 (en) 2015-02-27 2020-05-06 Gemvax & Kael Co., Ltd. Peptide for preventing hearing loss, and composition comprising same
US11015179B2 (en) 2015-07-02 2021-05-25 Gemvax & Kael Co., Ltd. Peptide having anti-viral effect and composition containing same
EP3441082B1 (en) 2016-04-07 2023-06-21 Gemvax & Kael Co., Ltd. Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030211B1 (en) 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
WO2003038047A2 (en) * 2001-10-29 2003-05-08 Baylor College Of Medicine Human telomerase reverse transcriptase as a class-ii restricted tumor-associated antigen
ITMI20032121A1 (it) * 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi

Also Published As

Publication number Publication date
HRP20161434T1 (hr) 2017-02-24
US8828403B2 (en) 2014-09-09
PT2310044T (pt) 2016-11-18
CY1118215T1 (el) 2017-06-28
JP2011524390A (ja) 2011-09-01
HUE030984T2 (en) 2017-06-28
CA2727388A1 (en) 2010-01-14
LT2310044T (lt) 2016-12-27
DK2310044T3 (en) 2016-12-12
US20110135692A1 (en) 2011-06-09
CA2727388C (en) 2017-08-29
WO2010003520A3 (en) 2010-07-15
EP2310044B1 (en) 2016-08-24
WO2010003520A2 (en) 2010-01-14
SI2310044T1 (sl) 2017-03-31
JP5787752B2 (ja) 2015-09-30
ES2602453T3 (es) 2017-02-21
EP2310044A2 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
SI2310044T1 (sl) Proti-tumorska imunoterapija
EP2376105A4 (en) NKG2D-FC FOR IMMUNOTHERAPY
EP2150618A4 (en) IL-12 IMMUNOTHERAPY AGAINST CANCER
EP2341897A4 (en) NANOPARTICLES FOR IMMUNOTHERAPY
EP2429585A4 (en) VACCINE IMMUNOTHERAPY
IL210818A0 (en) Gemstone viewer
IL208990A0 (en) Novel phenylimidazopyrazines
EP2323928A4 (en) CARRIER ASSEMBLY
EP2056861A4 (en) IMPF-IMMUNOTHERAPY
GB0815216D0 (en) Interleukin
GB2451357B (en) Ceramic Armour
HK1132673A1 (en) Novel methods
IL207958A0 (en) Allogeneic cancer cell - based immunotherapy
GB0806569D0 (en) Methods
PL2234635T3 (pl) Immunoterapia oparta na białkach rhoc
GB0811360D0 (en) Methods
HK1149235A1 (en) Fixture means
EP2161998A4 (en) NOVEL PROCEDURE
GB0817482D0 (en) No-catch zip
GB0812589D0 (en) Adoptive immunotherapy
GB0711729D0 (en) Adoptive immunotherapy
GB0712715D0 (en) Adoptive immunotherapy
AU2008903232A0 (en) Cancer immunotherapy
AU2009903449A0 (en) Cancer Immunotherapy
GB0811114D0 (en) Mud-monster + tail-safe